Sino Biopharmaceutical Limited (OTCMKTS:SBMFF - Get Free Report) saw a significant increase in short interest in October. As of October 15th, there was short interest totalling 1,203,300 shares, an increase of 755.8% from the September 30th total of 140,600 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Sino Biopharmaceutical Stock Performance
Sino Biopharmaceutical stock remained flat at $0.47 during mid-day trading on Friday. The firm has a 50 day moving average price of $0.42 and a two-hundred day moving average price of $0.37. Sino Biopharmaceutical has a 1-year low of $0.31 and a 1-year high of $0.49.
About Sino Biopharmaceutical
(
Get Free Report)
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sino Biopharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sino Biopharmaceutical wasn't on the list.
While Sino Biopharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
